The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
RNA expression levels from peripheral immune cells, a minimally invasive liquid biopsy source to predict response to therapy, survival and immune-related adverse events in patients with triple negative breast cancer enrolled in the GeparNuevo trial.
 
Hanna Huebner
Employment - Institut fuer Frauengesundheit GmbH
 
Matthias Rübner
No Relationships to Disclose
 
Andreas Schneeweiss
Honoraria - Amgen; AstraZeneca/Daiichi Sankyo; Aurikamed; Bayer; Celgene; ClinSol; Connectmedica; Gilead Sciences; GlaxoSmithKline; I-MED; Lilly; MCI Deutschland; Metaplan; MSD; NanoString Technologies; Novartis; Onkowissen; Pfizer; Pierre Fabre; Promedicis; Roche; Seagen; Streamedup!; Tesaro; Teva; Thieme
Research Funding - Celgene (Inst); Roche Pharma AG (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Celgene; Pfizer; Roche
 
Carsten Denkert
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Lilly; Molecular Health; MSD Oncology; Roche
Research Funding - German Breast Group (Inst); Myriad Genetics (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - Patent WO2010076322A1; Patent WO2015114146A1; Patent WO2020109570A1; VMScope digital pathology software
 
Hans Peter Sinn
Honoraria - NanoString Technologies; Roche
Research Funding - Roche
Travel, Accommodations, Expenses - NanoString Technologies
 
Michael Braun
Consulting or Advisory Role - Daiichi Sankyo/Astra Zeneca; Exact Sciences; Gilead Sciences; Novartis; Pfizer
Speakers' Bureau - Exact Sciences; Novartis
 
Thomas Karn
Patents, Royalties, Other Intellectual Property - Patent WO2020109570A1
 
Bruno Valentin Sinn
Patents, Royalties, Other Intellectual Property - Patent pending WO2017189976A1; Patent pending WO2020109570A1
 
Dirk Michael Zahm
No Relationships to Disclose
 
Jörg Thomalla
No Relationships to Disclose
 
Jens Bodo Huober
Honoraria - Abbvie; AstraZeneca; Celgene; Celgene; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Lilly; MSD Oncology; Novartis; Pfizer; Roche; Seagen
Consulting or Advisory Role - Abbvie; AstraZeneca; Celgene; Daiichi Sankyo/Astra Zeneca; Eisai; Hexal; Lilly; MSD Oncology; Novartis; Pfizer; Roche
Research Funding - Celgene (Inst); Hexal; Lilly (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Celgene; Daiichi Sankyo; Novartis; Pfizer; Roche
(OPTIONAL) Uncompensated Relationships - German Breast Group
 
Claus Hanusch
Consulting or Advisory Role - Amgen; AstraZeneca; Celgene; Novartis; Pfizer; Roche
Speakers' Bureau - Celgene; Lilly O.; Novartis; Pfizer; Roche
 
Michael Untch
Honoraria - Agendia (Inst); Amgen (Inst); Art tempi (Inst); AstraZeneca (Inst); Baxter (Inst); Daiji Sankyo (Inst); Eisai Europe (Inst); Gilead Sciences (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche Pharma AG (Inst); Sanofi (Inst); Seagen (Inst)
Consulting or Advisory Role - Agendia (Inst); Amgen (Inst); Art tempi (Inst); AstraZeneca (Inst); Daiichi Sankyo Europe GmbH (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Medac (Inst); MSD Oncology (Inst); Myriad Genetics (Inst); Novartis (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche Pharma AG (Inst); Sanofi Aventis GmbH (Inst)
 
Christine Solbach
Honoraria - AstraZeneca; MSD; Novartis; Pfizer; Roche
Consulting or Advisory Role - MSD; Roche
Speakers' Bureau - Dialog Service GmbH; Eickeler; MedConcept
Travel, Accommodations, Expenses - Novartis; Novartis; Pfizer; Roche
 
Theresa Link
Honoraria - Amgen; AstraZeneca; Daiichi Sankyo Pharmaceutical; Gilead Sciences; GlaxoSmithKline; Novartis; Pfizer; Roche
Consulting or Advisory Role - Daiichi Sankyo Pharmaceutical; Eisai; Gilead Sciences; GlaxoSmithKline; Lilly O.; MSD; Myriad Genetic Laboratories; Novartis; Pfizer; Pfizer; Roche
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo Pharmaceutical; Gilead Sciences; Pfizer
 
Natalie Filmann
Research Funding - Abbvie (Inst); AstraZeneca (Inst); BMS GmbH & Co. KG (Inst); Daiichi Sankyo Pharmaceutical (Inst); Gilead Sciences (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - EP14153692.0 (Inst); EP15702464.7 (Inst); EP19808852.8 (Inst); EP21152186.9 (Inst); VM Scope GmbH (Inst)
Other Relationship - Daiichi Sankyo Pharmaceutical (Inst); Gilead Sciences (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Seagen (Inst)
 
Julia Rey
Research Funding - Abbvie (Inst); AstraZeneca (Inst); BMS Brazil (Inst); Daiichi Sankyo Pharmaceutical (Inst); Gilead Sciences (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - EP14153692.0 (Inst); EP15702464.7 (Inst); EP19808852.8 (Inst); EP21152186.9 (Inst); VM Scope GmbH (Inst)
Other Relationship - Daiichi Sankyo Pharmaceutical (Inst); Gilead Sciences (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Seagen (Inst)
 
Sibylle Loibl
Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Daiichi Sankyo (Inst); EirGenix (Inst); Eisai Europe (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Lilly (Inst); Merck KGaA (Inst); Novartis (Inst); Olema Pharmaceuticals (Inst); Pfizer (Inst); Pierre Fabre (Inst); Relay Therapeutics (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst)
Speakers' Bureau - AstraZeneca (Inst); Daiichi Sankyo Europe GmbH (Inst); Gilead Sciences (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Seagen (Inst)
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Celgene (Inst); Daiichi Sankyo (Inst); Gilead Sciences (Inst); MolecularHealth (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - Digital Ki67 Evaluator, VM Scope GmbH (Inst); Patent Issued EP15702464.7 (Inst); Patent Pending EP14153692.0 (Inst); Patent Pending EP19808852.8 (Inst); Patent Pending EP21152186.9 (Inst)
 
Peter A. Fasching
Honoraria - Agendia; AstraZeneca; BionTech (Inst); Cepheid (Inst); Daiichi Sankyo; Eisai; Gilead Sciences; Hexal; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Pierre Fabre; Roche; Seagen
Consulting or Advisory Role - Agendia; AstraZeneca; Daiichi Sankyo; Eisai; Gilead Sciences; Hexal; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Pierre Fabre; Roche; Seagen
Research Funding - BioNTech (Inst); Cepheid (Inst); Novartis (Inst); Roche